Navigation Links
Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
Date:12/5/2013

INDIANAPOLIS, Dec. 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor (SSRI), edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale (MADRS) in three acute randomized placebo-controlled Phase III studies (LNBM, LNBQ and LNBR).

While the safety and tolerability of edivoxetine was consistent with previous studies, the efficacy results do not support a regulatory submission for adjunctive treatment in patients with Major Depressive Disorder (MDD). Data from all three studies will be disclosed in appropriate scientific forums in 2014.

In 2010, Lilly launched the Phase III program for edivoxetine – a potent and highly selective norepinephrine reuptake inhibitor – to assess the benefits and risks of edivoxetine as an add-on therapy in patients with MDD.  The Phase III program specifically focused on meeting the unmet needs of patients with major depression who had achieved only a partial response to treatment with an SSRI.  In these three trials, patients remained on SSRI treatment and additionally received either edivoxetine or placebo. 

"Lilly undertook a robust Phase III program to address a significant unmet need for people suffering from depression," said David Ricks, senior vice president, and president, Lilly Bio-Medicines. "However, the lack of efficacy compared to SSRI alone in three separate clinical trials means that Lilly will not proceed with development of edivoxetine as an add-on treatment for depression." The ongoing clinical study evaluating the long-term maintenance effect of edivoxetine will continu
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zacks Industry Outlook Highlights: Merck, Pfizer, Forest Laboratories, Sanofi and Eli Lilly
2. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
3. Surveyed Endocrinologists Consider Eli Lillys Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin
4. Lilly Statement on Contribution to Indiana Biosciences Research Institute
5. Lilly Announces Significant Global Insulin Manufacturing Capacity Investments in Response to Growing Diabetes Epidemic
6. Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes
7. Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets
8. Lilly Reports Third-Quarter 2013 Results
9. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
10. Lilly Declares Fourth-Quarter 2013 Dividend
11. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Women everywhere ... infections are not only uncomfortable, they,re often also embarrassing ... plans. pH-D Feminine Health Support ( http://ph-defense.com ) is ... It is an all-natural, homeopathic product. ... common symptoms of vaginal infection. In many cases, the ...
(Date:9/17/2014)... LOS ANGELES and LEIPZIG, ... Inc. today announced that it has entered into ... for the development of antibody-based imaging agents to ... "Our collaboration with Novotectid expands ImaginAb,s capability to ... the immune-oncology and autoimmune disease areas. The ability ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
Breaking Medicine Technology:New Product from Vireo Systems: pH-D Feminine Health Support 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... Ind., Oct. 20, 2011 Hill-Rom Holdings, Inc., (NYSE: ... a management presentation at the Credit Suisse,s 2011 Healthcare ... p.m. ET. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at ...
... Oct. 20, 2011 The Academy of Managed ... Conference in Atlanta. The conference, Oct. 19-21, draws ... and features a wide range of programs and ... sessions, student pharmacist programming, networking events and other ...
Cached Medicine Technology:Academy of Managed Care Pharmacy Opens 2011 Educational Conference in Atlanta 2
(Date:9/17/2014)... In its latest blog post, Best Drug Rehabilitation , ... by during a stay in rehab can make a big ... highlighting a member of the therapeutic care team that is ... the country and around the world: dogs. , ... heart rate, and stress levels in recovering addicts,” commented Best ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Dennis Thompson ... News) -- Exposure in the womb to household chemicals ... of developing asthma, Columbia University researchers reported in a ... increased risk of developing asthma between age 5 and ... high levels of two phthalates (pronounced thal-ates), the researchers ...
(Date:9/17/2014)... 17, 2014Scientists at The Scripps Research Institute (TSRI) ... that is powerfully effective against vancomycin-resistant strains of ... vancomycin analog appears to have not one but ... bacteria probably cannot evolve resistance quickly. , "This ... will still be in clinical use a generation ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... HealthDay Reporter , TUESDAY, Oct. 26 (HealthDay News) ... could be prevented if people followed five simple healthy ... which would improve overall health as well -- include ... maintaining a healthy weight, the researchers say. "Even ...
... respond to hormonal changes and inflammation has been awarded ... five-year study. The research programme at the National ... is led by Professor Julian Davis, a consultant endocrinologist ... of Manchester,s Developmental Biomedicine Research Group. He is ...
... Professor Zhipeng Wu has invented a portable scanner based on radio ... presence of tumours malignant and benign in the breast ... breast cancer detection has been proven by researchers in the US, ... few minutes for an image to be produced, and this had ...
... is not considered effective treatment for KRAS (a gene)-mutated ... colorectal cancer not responding to chemotherapy and a certain ... had longer overall and progression-free survival than patients with ... 27 issue of JAMA . "Recent ...
... TUESDAY, Oct. 26 (HealthDay News) -- Children who survive ... on, a new study suggests. The findings highlight ... among childhood cancer survivors, the researchers said. "Current ... cancer, but we know that many cancer therapies -- ...
... 26 (HealthDay News) -- Primary care doctors earn the ... one reason for U.S. medical students, declining interest in ... at the wages of 6,381 physicians providing patient care ... primary care; surgery; internal medicine and pediatric subspecialties; and ...
Cached Medicine News:Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 2Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 3Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:Portable breast scanner allows cancer detection in the blink of an eye 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2Health News:Childhood Cancer Survivors Risk Future GI Problems 2Health News:Primary Care MDs at Low End of Pay Scale, Study Finds 2
... androgen secreted into the blood. In males, ... of the testes; in females ca. 50% ... of androstenedione, ca. 25% from the ovary ... The Testosterone ELISA KIT is based on ...
Microalbumin EIA Lipid / Protein Quantification 024-IDC-12...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: